MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 30.28 Billion KRW | 18.01% |
| 2022 | 25.65 Billion KRW | -1.43% |
| 2021 | 26.03 Billion KRW | -13.93% |
| 2020 | 30.24 Billion KRW | 15.98% |
| 2019 | 26.07 Billion KRW | 27.54% |
| 2018 | 20.44 Billion KRW | -2.25% |
| 2017 | 20.91 Billion KRW | 9.42% |
| 2016 | 19.11 Billion KRW | 3.95% |
| 2015 | 18.38 Billion KRW | 5.09% |
| 2014 | 17.49 Billion KRW | 6.2% |
| 2013 | 16.47 Billion KRW | -9.0% |
| 2012 | 18.1 Billion KRW | 13.2% |
| 2011 | 15.99 Billion KRW | 23.48% |
| 2010 | 12.95 Billion KRW | 8.29% |
| 2009 | 11.96 Billion KRW | 36.14% |
| 2008 | 8.78 Billion KRW | 42.78% |
| 2007 | 6.15 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 31.41 Billion KRW | 1.58% |
| 2024 Q1 | 30.92 Billion KRW | 2.13% |
| 2023 Q2 | 31.72 Billion KRW | 9.77% |
| 2023 FY | 30.28 Billion KRW | 18.01% |
| 2023 Q1 | 28.89 Billion KRW | 12.62% |
| 2023 Q4 | 30.28 Billion KRW | -6.01% |
| 2023 Q3 | 32.21 Billion KRW | 1.56% |
| 2022 Q2 | 27.03 Billion KRW | -1.12% |
| 2022 Q4 | 25.65 Billion KRW | -5.15% |
| 2022 Q1 | 27.33 Billion KRW | 5.02% |
| 2022 FY | 25.65 Billion KRW | -1.43% |
| 2022 Q3 | 27.05 Billion KRW | 0.08% |
| 2021 Q1 | 32.46 Billion KRW | 7.34% |
| 2021 Q2 | 30.78 Billion KRW | -5.18% |
| 2021 FY | 26.03 Billion KRW | -13.93% |
| 2021 Q4 | 26.03 Billion KRW | -12.45% |
| 2021 Q3 | 29.73 Billion KRW | -3.42% |
| 2020 FY | 30.24 Billion KRW | 15.98% |
| 2020 Q1 | 28.7 Billion KRW | 10.08% |
| 2020 Q4 | 30.24 Billion KRW | 5.28% |
| 2020 Q3 | 28.72 Billion KRW | -2.65% |
| 2020 Q2 | 29.51 Billion KRW | 2.8% |
| 2019 Q1 | 23.17 Billion KRW | 13.35% |
| 2019 Q4 | 26.07 Billion KRW | -3.37% |
| 2019 Q3 | 26.98 Billion KRW | 1.62% |
| 2019 Q2 | 26.55 Billion KRW | 14.59% |
| 2019 FY | 26.07 Billion KRW | 27.54% |
| 2018 Q1 | 20.73 Billion KRW | -0.89% |
| 2018 Q3 | 22.19 Billion KRW | 6.01% |
| 2018 Q4 | 20.44 Billion KRW | -7.88% |
| 2018 FY | 20.44 Billion KRW | -2.25% |
| 2018 Q2 | 20.93 Billion KRW | 0.99% |
| 2017 Q4 | 20.91 Billion KRW | 8.93% |
| 2017 Q3 | 19.2 Billion KRW | 1.86% |
| 2017 Q2 | 18.85 Billion KRW | -8.65% |
| 2017 Q1 | 20.63 Billion KRW | 7.96% |
| 2017 FY | 20.91 Billion KRW | 9.42% |
| 2016 FY | 19.11 Billion KRW | 3.95% |
| 2016 Q1 | 18.03 Billion KRW | -1.93% |
| 2016 Q2 | 18.72 Billion KRW | 3.82% |
| 2016 Q3 | 18.33 Billion KRW | -2.08% |
| 2016 Q4 | 19.11 Billion KRW | 4.27% |
| 2015 Q1 | 21.09 Billion KRW | 20.57% |
| 2015 Q2 | 18.41 Billion KRW | -12.71% |
| 2015 Q4 | 18.38 Billion KRW | 5.15% |
| 2015 FY | 18.38 Billion KRW | 5.09% |
| 2015 Q3 | 17.48 Billion KRW | -5.04% |
| 2014 Q2 | 15.87 Billion KRW | -6.82% |
| 2014 FY | 17.49 Billion KRW | 6.2% |
| 2014 Q4 | 17.49 Billion KRW | 15.19% |
| 2014 Q3 | 15.19 Billion KRW | -4.31% |
| 2014 Q1 | 17.03 Billion KRW | 3.41% |
| 2013 Q1 | 17.24 Billion KRW | -4.76% |
| 2013 Q3 | 17.38 Billion KRW | 1.06% |
| 2013 Q4 | 16.47 Billion KRW | -5.25% |
| 2013 FY | 16.47 Billion KRW | -9.0% |
| 2013 Q2 | 17.2 Billion KRW | -0.23% |
| 2012 Q4 | 18.1 Billion KRW | 0.0% |
| 2012 Q1 | 15.93 Billion KRW | 0.0% |
| 2012 FY | 18.1 Billion KRW | 13.2% |
| 2011 FY | 15.99 Billion KRW | 23.48% |
| 2011 Q3 | 14.93 Billion KRW | 0.0% |
| 2011 Q2 | 14.93 Billion KRW | 5.58% |
| 2011 Q1 | 14.14 Billion KRW | 0.0% |
| 2010 Q2 | 10.99 Billion KRW | -21.8% |
| 2010 Q1 | 14.06 Billion KRW | 0.0% |
| 2010 Q3 | 10.88 Billion KRW | -1.01% |
| 2010 FY | 12.95 Billion KRW | 8.29% |
| 2009 Q1 | 9.55 Billion KRW | 8.76% |
| 2009 FY | 11.96 Billion KRW | 36.14% |
| 2009 Q3 | 15.15 Billion KRW | 20.45% |
| 2009 Q2 | 12.57 Billion KRW | 31.63% |
| 2008 Q2 | 7.16 Billion KRW | 0.0% |
| 2008 Q3 | 8.25 Billion KRW | 15.16% |
| 2008 FY | 8.78 Billion KRW | 42.78% |
| 2008 Q4 | 8.78 Billion KRW | 6.46% |
| 2007 FY | 6.15 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 31.418% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 74.307% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 66.786% |
| HANDOK Inc. | 94.46 Billion KRW | 67.945% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -42.542% |
| Yuhan Corporation | 284.75 Billion KRW | 89.366% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 73.967% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -86.24% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 89.516% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 6.497% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 50.943% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -55.466% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 37.369% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 31.418% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | 3.075% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 13.919% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 37.084% |
| JW Holdings Corporation | 147.58 Billion KRW | 79.483% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 64.218% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 88.418% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 71.458% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 43.846% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -12.157% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 6.863% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 72.414% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 31.418% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 83.948% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 87.464% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 71.458% |
| Yuhan Corporation | 284.75 Billion KRW | 89.366% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 75.83% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 51.15% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 88.347% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 71.458% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 61.961% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 38.382% |
| CKD Bio Corp. | 69.08 Billion KRW | 56.168% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 71.183% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 57.169% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 43.986% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 43.846% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 84.453% |
| Boryung Corporation | 189.8 Billion KRW | 84.047% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 46.72% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 50.943% |
| JW Lifescience Corporation | 23.39 Billion KRW | -29.41% |